Sepsis results in significant morbidity and mortality, with current treatment options limited with respect to efficacy as well as safety. The complex homeopathic remedy Traumeel S has been shown to have both anti-inflammatory and immunostimulatory effects in the in vitro setting.
Objectives:
The objective was to explore the effects of Traumeel S in an in vivo setting, using a cecal ligation and puncture (CLP) sepsis model in rats, evaluating the effects of the medication on cytokine activity.
Design:
Sepsis was induced in 30 rats using accepted CLP methodology. Following the procedure, rats were randomly allocated to receive an intraperitoneal injection of either Traumeel S (n=15) or normal saline (n=15). At 6 hours post-CLP, serum cytokines (interleukin [IL]-1β, tumor necrosis factor-α, IL-6, and IL-10) were evaluated.
Results:
IL-1β levels were significantly higher in the treatment group (p=0.03) with no significant differences found between the groups with respect to the other cytokines tested.
Conclusions:
In contrast to in vitro studies, Traumeel significantly increased IL-1β levels in an in vivo model, without influencing other cytokines. IL-1β is a proinflammatory cytokine that has been shown to have a protective effect in the CLP rat model. Further research is warranted to examine this finding, as well as its clinical implications.
Get full access to this article
View all access options for this article.
References
1.
AngusDC, Linde-ZwirbleWT, LidickerJet al.Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med, 2001; 29:1303–1310.
2.
VincentJL, AbrahamE. The last 100 years of sepsis (Centennial Review)Am J Resp Crit Care Med, 2005; 173:256–263.
3.
BernardGR, ElyEW, WrightTJet al.Efficacy and safety of recombinant human activated protein C for severe sepsis. NEJM, 2001; 344:699–709.
4.
RiceTW, BernardGR. Therapeutic intervention and targets for sepsis. Annu Rev Med, 2005; 56:225–248.
5.
National Center for Complementary Alternative Medicine. Homeopathy: An Introduction. http://nccam.nih.gov/homeopathy/. 2011 January 20.
6.
ZellJ, ConnertWD, MauJ. Treatment of acute sprains of the ankle joint: Double-blind study assessing the effectiveness of a homeopathic ointment preparation [in German]Fortschr Med, 1988; 106:96–100.
7.
BohmerD, AmbrusP. Treatment of sports injuries with Traumeel ointment. Biol Ther, 1989; 10:290–300.
8.
MergenH. Treatment of post-traumatic swelling with Traumeel: Contribution to the relationship “dosage:effect” of a combination drug [in German]Munch Med Wochenschr, 1969; 111:298–300.
9.
GrudianovAI, BezrukovaIV, AleksandrovskaiaI. Comparative study of homeopathic remedies clinical efficacy in comprehensive treatment of inflammatory periodontal diseases in patients with burdened allergic status [in Russian]Stomatologiia (Mosk), 2006; 85:25–28.
10.
OberbaumM, YanivI, Ben GalYet al.A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Cancer, 2001; 92:684–690.
11.
PorozovS, CahalonL, WeiserMet al.Inhibition of IL-1β and TNF-alpha secretion from resting and activated human immunocytes by the homeopathic medication Traumeel S. Clin Develop Immunol, 2004; 11:143–149.
12.
LussignoliS, BertaniS, MetelmannHet al.Effect of Traumeel S, a homeopathic formulation, on blood-induced inflammation in rats. Complement Ther Med, 1999; 7:225–230.
13.
WichtermanKA, BaueAE, ChaudryIH. Sepsis and septic shock: A review of laboratory models and a proposal. J Surg Res, 1980; 2:189–201.
14.
HerschM, MadorinWS, SibbaldWJ, MartinCM. Selective gut microcirculatory control (SGMC) in septic rats: A novel approach with a locally applied vasoactive drug. Shock, 1998; 10:292–297.
15.
TorossianA, RuehlmannS, MiddekeMet al.Mild preseptic hypothermia is detrimental in rats. Crit Care Med, 2004; 32:1899–1903.
16.
RothshenkerS, AamarS, BarakV. Interleukin 1 activity in injured peripheral nerve and roles in nerve repair mechanisms. J Neuroimmunol, 1992; 39:75–80.
17.
AvinerS, BerkovitchM, DalkianHet al.Use of a homeopathic preparation for “infantile colic” and an apparent life-threatening event. Pediatrics, 2010; 125:e318–e323.
18.
KuenzliS, GrimaîtreM, KrischerJet al.Childhood bullous pemphigoid: Report of a case with life-threatening course during homeopathy treatment. Pediatr Dermatol, 2004; 21:160–163.
19.
AngusDC, Linde-ZwirbleWT, LidickerJet al.Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med, 2001; 29:1303–1310.
20.
BozzaFA, SalluhJI, JapiassuAMet al.Cytokine profiles as markers of disease severity in sepsis: A multiplex analysis. Crit Care, 2007; 11:R49–R56.
21.
DimopoulouI, OrfanosS, KotanidouAet al.Plasma pro- and anti-inflammatory cytokine levels and outcome prediction in unselected critically ill patients. Cytokine, 2008; 41:263–267.
22.
SingletonKD, WischmeyerPE. Distance of cecum ligated influences mortality, tumor necrosis factor-alpha and interleukin-6 expression following cecal ligation and puncture in the rat. Eur Surg Res, 2003; 35:486–491.
23.
RemickDG, CallDR, EbongSJet al.Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit Care Med, 2001; 29:473–481.
HorinoT, MatsumotoT, UramatsuMet al.Interleukin-1-deficient mice exhibit high sensitivity to gut-derived sepsis caused by Pseudomonas aeruginosa. Cytokine, 2005; 30:339–346.
26.
CampanileF, BinagliaL, BoraschiDet al.Antibacterial resistance induced by recombinant interleukin 1 in myelosuppressed mice: Effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream. Cell Immunol, 1990; 128:250–260.
27.
VogelsMT, HermsenCC, HuysHLet al.Roles of tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice. Infect Immun, 1994; 62:2065–2070.
28.
AlexanderHR, DohertyGM, FrakerDLet al.Human recombinant interleukin-1 alpha protection against the lethality of endotoxin and experimental sepsis in mice. J Surg Res, 1991; 50:421–424.
29.
TadrosT, TraberDL, HeggersJP, HerndonDN. Effects of interleukin-1alpha administration on intestinal ischemia and reperfusion injury, mucosal permeability, and bacterial translocation in burn and sepsis. Ann Surg, 2003; 237:101–109.
30.
O'ReillyM, SilverGM, DavisJHet al.Interleukin 1 beta improves survival following cecal ligation and puncture. J Surg Res, 1992; 52:518–522.
31.
LugerA, GrafH, SchwarzHPet al.Decreased serum interleukin 1 activity and monocyte interleukin 1 production in patients with fatal sepsis. Crit Care Med, 1986; 14:458–461.
32.
MatsumotoT, TatedaK, MiyazakiSet al.Paradoxical synergistic effects of tumour necrosis factor and interleukin 1 in murine gut-derived sepsis with Pseudomonas aeruginosa. Cytokine, 1999; 11:366–372.
33.
AmuraCR, FontanPA, SanjuanN, SordelliDO. The effect of treatment with interleukin-1 and tumor necrosis factor on Pseudomonas aeruginosa lung infection in a granulocytopenic mouse model. Clin Immunol Immunopathol, 1994; 73:261–266.
34.
KendigEL, LeHH, BelcherSM. Defining hormesis: Evaluation of a complex concentration response phenomenon. Int J Toxicol, 2010; 29:235–246.
35.
JensenLE, MuzioM, MantovaniA, WhiteheadAS. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol, 2000; 164:5277–5286.
36.
GemsD, PartridgeL. Stress-response hormesis and aging: "That which does not kill us makes us stronger"Cell Metab, 2008; 7:200–203.
37.
CalabreseEJ, BachmannKA, BailerAJet al.Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol Appl Pharmacol, 2007; 222:122–128.
38.
CalabreseEJ. Paradigm lost, paradigm found: The re-emergence of hormesis as a fundamental dose response model in the toxicological sciences. Environ Pollut, 2005; 138:379–411.
39.
FrassM, LinkeschM, BanyaiSet al.Adjunctive homeopathic treatment in patients with severe sepsis: A randomized, double-blind, placebo-controlled trial in an intensive care unit. Homeopathy, 2005; 94:75–80.
